Radiesse uses calcium hydroxylapatite (CaHA) to provide volume and stimulate collagen, while Restylane uses hyaluronic acid (HA) gels with product-specific properties. The clinical choice depends on the treatment area, tissue characteristics, and options for managing an unwanted result.
This Radiesse vs Restylane comparison for injectors focuses on those differences rather than broad claims about which brand lasts longer or provides more lift.
Radiesse vs Restylane at a Glance
The largest practical difference is the material and what can happen if its placement or effect needs correction.
| Clinical factor | Radiesse | Restylane |
| Material | CaHA microspheres in a gel carrier | Cross-linked HA gels |
| Main mechanism | Immediate correction plus collagen stimulation | Volume and support from HA gel; properties vary by product |
| Product distinctions | Radiesse and Radiesse (+), which contains lidocaine, have different labels | Lyft, Contour, Kysse, Eyelight, and other formulations have separate labels |
| Enzymatic dissolution | No approved CaHA-dissolving agent | Hyaluronidase can degrade HA; aesthetic use is off-label |
| Structural applications | Radiesse (+) has a jawline contour indication | Lyft, Defyne, and Contour include structural indications in specific areas |
| Shared labeled uses | Facial wrinkles and folds; Radiesse also covers dorsal hand volume loss | Several products cover facial folds; Lyft covers dorsal hand volume loss |
| Serious complication risk | Intravascular injection can cause tissue necrosis, blindness, or stroke | The same serious vascular risks apply |
Differences Between Radiesse and Restylane Start With the Material
The differences between Radiesse and Restylane affect tissue support, product placement, and correction options. Neither material has one universal role across every anatomical area.
Radiesse Provides Correction and a Collagen Response
Radiesse contains synthetic CaHA microspheres suspended in a carrier of water, glycerin, and sodium carboxymethylcellulose. The carrier contributes to the initial correction, while the CaHA component supports subsequent collagen formation. Radiesse is biodegradable rather than permanent.
Dilution changes the intended treatment effect. A diluted skin-quality treatment and an undiluted contouring treatment cannot be treated as interchangeable procedures simply because they use the same brand.
The Radiesse clinical product information distinguishes its current treatment uses and safety information. Radiesse belongs to the Merz product portfolio; its brand relationship does not make other Merz injectables equivalent materials.
Restylane Includes Both Firm and Flexible HA Gels
Restylane is a product family, not a single gel. Galderma groups its U.S. formulations into NASHA and XpresHAn technologies, with differences in texture, flexibility, and intended tissue support.
Lyft can provide structural support in the cheek or chin, while Kysse has a lip indication. Eyelight addresses infraorbital hollowing, while Contour has indications for cheek augmentation, midface contour deficiencies, and correction of temple hollowing in adults over 21.
Describing all Restylane products as soft fillers for superficial placement misses these distinctions.
Radiesse vs Restylane Treatment Areas: Match the Exact Product
Radiesse vs Restylane treatment areas overlap for facial folds and dorsal hand volume loss. Elsewhere, the relevant indication belongs to a particular formulation, not to the brand name alone.
| Treatment goal | Radiesse labeling | Restylane labeling |
| Moderate to severe facial wrinkles and folds | Radiesse and Radiesse (+) | Restylane/Restylane-L, Lyft, Refyne, and Defyne, with product-specific wording |
| Dorsal hand volume loss | Radiesse | Lyft |
| Moderate to severe loss of jawline contour | Radiesse (+) | No specific U.S. jawline contour indication in the current Restylane family labels reviewed |
| Lip augmentation | No established safety and effectiveness for lip use | Restylane/Restylane-L, Silk, and Kysse |
| Perioral wrinkles | No dedicated perioral wrinkle indication | Silk; Kysse covers upper perioral wrinkles |
| Infraorbital hollowing | No established safety and effectiveness for periorbital use | Eyelight |
| Cheek augmentation and midface contour deficiencies | No specific cosmetic cheek augmentation indication | Lyft and Contour |
| Chin augmentation for mild to moderate retrusion | No specific chin augmentation indication | Defyne and Lyft |
| Temple hollowing | No specific temple indication | Contour |
| Décolleté wrinkles | Radiesse diluted 1:2 with 0.9% sterile saline, for patients aged 22 and older | No corresponding U.S. indication in the labels reviewed |
Recent Approvals Change Older Comparisons
Restylane Lyft added a U.S. chin indication in late 2025. The FDA approved Contour for temple hollowing on March 20, 2026, and Radiesse for décolleté wrinkles on March 31, 2026. Manufacturer announcements followed on March 23 and April 8, respectively.
The décolleté label includes conditions that a general comparison can overlook. It requires indication-specific training and restricts placement to the defined subdermal treatment area, away from overlying breast tissue.
Approval of that protocol does not establish every diluted CaHA face or body treatment as an approved use.
An on-label option narrows the choice; it does not establish that filler treatment is appropriate for every patient with that concern.
Which Lasts Longer? Read the Trial Before Choosing a Winner
Duration evidence supports particular products, treatment areas, and schedules. It does not establish that Radiesse always outlasts every Restylane formulation.
Moers-Carpi and Tufet’s 2008 randomized split-face trial enrolled 60 patients with nasolabial folds. Patients received CaHA on one side and nonanimal stabilized HA on the other, with two injection sessions three months apart.
At 12 months, evaluators rated 79% of CaHA-treated folds as improved or better, compared with 43% of HA-treated folds.
That result favors CaHA under the study’s conditions. It does not compare Radiesse with today’s full Restylane portfolio, establish a duration advantage in the hands, or predict lip and temple outcomes.
Modern HA data also extends beyond a generic six-month estimate. Galderma reports results lasting up to 18 months for Contour-treated temple hollowing. That is a different product, anatomical area, and study, so the figures cannot support a direct comparison with the older nasolabial-fold trial.
Radiesse or Restylane: Which Is Better for Sustained Correction?
The answer depends on the formulation, treated area, and evidence behind the proposed treatment.
A useful Radiesse vs Restylane comparison for injectors identifies those study conditions before interpreting a duration claim.
The PubMed index of calcium hydroxylapatite research includes clinical trials and laboratory studies. Laboratory evidence of material behavior cannot, by itself, establish how long a patient’s visible correction will last.
How Radiesse Compares to Restylane HA When Correction Is Needed
Hyaluronidase can degrade HA; it does not dissolve CaHA microspheres. This difference affects informed consent and complication planning.
Understanding how Radiesse compares to Restylane HA requires separating three situations:
- An unwanted aesthetic result: HA dissolution may reduce misplaced or excessive product. That intervention has its own risks and may require repeat treatment.
- A palpable nodule: Diagnose the cause before selecting treatment. Product accumulation, inflammation, and infection do not call for the same response.
- Suspected vascular compromise: Stop injecting and activate an urgent management pathway. Skin ischemia and visual symptoms require different escalation routes.
The absence of a CaHA-dissolving enzyme does not mean there is no treatment pathway. Published CaHA vascular-complication guidance includes urgent interventions; some use hyaluronidase for proposed effects on surrounding tissue rather than CaHA dissolution. Those recommendations rely substantially on expert consensus.
The ability to dissolve HA does not guarantee recovery from vascular complications, tissue injury, or vision loss. Both brands require prevention, rapid recognition, and an established emergency referral plan.
Injection Technique Follows the Product and Anatomical Area
Depth and delivery method follow the exact product’s indication. The rule that Radiesse goes deep and Restylane goes superficially is inaccurate.
For example, Radiesse facial-fold labeling specifies subdermal implantation. Restylane Lyft’s cheek and chin indications include deeper planes, while Contour’s temple instructions include subdermal and supraperiosteal placement. The same HA brand can therefore involve substantially different tissue planes.
The Radiesse-Restylane provider comparison also changes when CaHA dilution forms part of the treatment. The labeled décolleté protocol specifies its diluent, ratio, delivery device, and training requirements. Technique for another area cannot be inferred from that protocol.
Neither a cannula nor a needle removes the possibility of intravascular injection. Anatomical assessment and product-specific training remain necessary with either instrument.
Patient Factors Can Change the Choice or Rule Out Treatment
- The cause of the concern: Hollowing, skin laxity, pigmentation, and edema are different problems. A label for infraorbital hollowing does not mean every dark circle needs filler.
- Previous treatments: Record existing fillers, their locations, prior surgery, and any earlier complications.
- Allergy and bleeding history: Review the exact product’s contraindications, including relevant lidocaine and bacterial-protein sensitivities.
- Active inflammation or infection: Defer treatment at affected sites until the condition is controlled.
- Pregnancy or breastfeeding: Safety has not been established.
- Expectations and reversibility: Explain the limits of both persistence and correction before treatment.
For a first-time patient who strongly values the possibility of reducing an unwanted result, an appropriate HA formulation may offer an advantage.
First-time status alone does not prove HA is clinically preferable, and a patient’s request for easy reversal does not make treatment suitable.
Imaging, Storage, and Cost Need Product-Specific Checks
Documentation and handling remain part of the comparison after the clinical decision.
CaHA Can Appear on Diagnostic Imaging
Radiesse’s CaHA particles are visible on CT and may appear on plain radiographs. Record the product and treated area, and explain why patients should disclose treatment to clinicians interpreting subsequent imaging.
The current décolleté label reports no interference with mammography or breast ultrasound in its supporting imaging study. It also identifies gaps for other imaging of the décolleté itself.
That supports disclosure and documentation rather than a blanket claim that CaHA prevents breast screening or never affects imaging.
Storage Requirements Are Not a Universal Cold-Chain Rule
The March 2026 Radiesse instructions specify storage at 15–32°C.
Restylane Lyft’s instructions specify up to 25°C, no freezing, and protection from sunlight; refrigeration is not required. Other formulations require their own label check.
Use the printed expiration date for each unit. Avoid applying one assumed shelf life or refrigerator setting to every filler in the clinic.
Acquisition Cost Does Not Establish Clinical Value
Compare cost per planned treatment rather than invoice price per syringe. Account for actual product volume, any planned touch-up, unused single-session product, and inventory expiry.
A larger syringe does not automatically provide proportionately more correction. Material behavior and the treated area affect the volume required, and one study’s volume savings cannot be assumed for unrelated procedures.
Supplier verification remains separate from product choice. For U.S. use, confirm the exact FDA-approved version, documented supply source, applicable distributor authorization, intact packaging, lot number, expiration date, and labeled handling.
A low price or familiar brand name cannot establish those facts.
Choosing Radiesse for Your Injectable Inventory
For practices that regularly treat concerns suited to CaHA, Radiesse can add a different option alongside an HA-based filler inventory. Its immediate structural correction, collagen-stimulating properties, and product-specific indications give it a distinct role rather than making it a direct substitute for every Restylane formulation.
Licensed practices can source wholesale Radiesse through DeWitt Pharma, with nationwide fulfillment and credential verification for eligible medical professionals.
Final Thoughts
The Radiesse vs Restylane decision is less about choosing a better filler and more about choosing the right material for the clinical goal. CaHA and HA differ in tissue behavior, approved uses, and options for managing unwanted results.
For injectors, the best choice starts with the treatment area, patient anatomy, desired outcome, and the exact product’s labeling, and not simply brand preference, price, or longevity.
Visit DeWitt Pharma’s full product page for more options and clinic needs.
Frequently Asked Questions
What is the main difference between Radiesse and Restylane?
The main difference is their materials. Radiesse contains CaHA microspheres and provides immediate correction with subsequent collagen stimulation. Restylane consists of cross-linked HA gels with different support and flexibility profiles depending on the formulation.
Another important difference is reversibility. Hyaluronidase can degrade HA, while it does not dissolve CaHA particles.
Which option lasts longer, Radiesse or Restylane?
There is no universal winner for longevity.
Radiesse showed more persistent nasolabial-fold improvement than the older HA comparator in a 2008 trial with two treatment sessions. Current Restylane products have their own area-specific duration data, including Contour temple results reported up to 18 months.
Whether Radiesse or Restylane lasts longer depends on the exact product, treatment area, and supporting evidence.
How do treatment goals affect product choice?
Treatment areas and indications differ by formulation. Lip augmentation or infraorbital hollowing directs attention to specific Restylane products. Radiesse (+) has a jawline-contour indication, while diluted Radiesse has a décolleté-wrinkle indication under its approved protocol.
Where indications overlap, providers should consider tissue needs, patient preferences, labeling, and complication planning.
Which product is better for first-time patients?
Neither product is automatically better simply because a patient is receiving filler for the first time.
A first-time patient who strongly values the possibility of reducing an unwanted result may prefer an appropriate HA formulation because HA can be degraded with hyaluronidase. Anatomy, treatment indication, contraindications, and realistic expectations should still determine suitability.
How do injection techniques differ between these products?
The exact formulation and treatment area determine injection depth and delivery method. A blanket rule that Radiesse is injected deeply while Restylane is injected superficially is inaccurate because both product families include indication-specific placement protocols.
Providers should follow current instructions and applicable training requirements for the selected product and treatment area.
What safety factors should providers compare?
Providers should consider contraindications, vascular risk, inflammatory complications, product components, previous procedures, treatment-area anatomy, and available correction options.
Both Radiesse and Restylane require appropriate complication protocols and urgent escalation for serious visual or neurological symptoms. CaHA’s imaging characteristics should also be documented when relevant.
How do wholesale costs affect product selection?
Wholesale cost should be considered after clinical suitability. Practices can compare the actual formulation, product volume, planned touch-ups, potential single-session waste, and inventory expiration when estimating treatment-level cost.
A lower acquisition price does not make a clinically unsuitable product an appropriate substitute.
Can both products be stocked in one clinic?
Yes. A clinic can stock both CaHA and HA products when its patient mix and staff competencies support their use.
Practices should maintain product-specific storage, expiration tracking, lot records, and complication protocols. Carrying both materials does not mean they are interchangeable or that using them together is appropriate for every patient.
What patient factors influence the final choice?
Providers should assess the treatment concern, tissue characteristics, previous fillers or surgery, allergies, bleeding history, and patient expectations.
Active infection or inflammation may require treatment to be deferred, and safety during pregnancy or breastfeeding has not been established. Correction limitations should also be discussed before treatment.
Where can licensed clinics order Radiesse?
Licensed medical practices can order Radiesse through DeWitt Pharma. Practices should verify the exact product and presentation needed, maintain appropriate acquisition records, and follow current manufacturer labeling and training requirements.
DeWitt Pharma verifies professional credentials and provides nationwide fulfillment for eligible medical practices.
